Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioNTech SE ( (BNTX) ) has issued an announcement.
BioNTech SE, a leading immunotherapy developer, is expanding its late-stage lung cancer pipeline with a mix of immunomodulators, antibody-drug conjugates and mRNA-based cancer therapies targeting multiple lung cancer subtypes. The company is running 16 clinical trials in lung cancer, including four pivotal Phase 3 studies and several novel combination regimens, underscoring its strategic push to address major unmet needs in this large oncology market.
On March 24, 2026, BioNTech announced it will present new clinical data at the European Lung Cancer Congress in Copenhagen from March 25–28, 2026, highlighting progress in key late-stage assets pumitamig, gotistobart and HER3-targeted ADC BNT326/YL202. Data from multiple China-based trials and a global Phase 3 study showed encouraging antitumor activity, survival benefits and manageable safety profiles across small cell and non-small cell lung cancer, potentially strengthening BioNTech’s competitive positioning in second-line and first-line lung cancer treatment settings.
The pumitamig program delivered updated results in first-line extensive-stage small cell lung cancer and advanced non-small cell lung cancer, as well as EGFR-mutant disease after tyrosine kinase inhibitor failure, supporting ongoing global ROSETTA Lung-01 and Lung-02 trials. Early data from BNT326/YL202 in previously treated NSCLC and its planned combination with pumitamig, together with gotistobart’s survival benefit and reduced risk of death versus standard chemotherapy in squamous NSCLC, may broaden BioNTech’s future commercial opportunities if these candidates advance successfully to approval.
The most recent analyst rating on (BNTX) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
The score is anchored by strong financial flexibility (low leverage and substantial resources) and constructive earnings-call updates (raised guidance and oncology progress), offset by weak current profitability and uneven cash generation. Technically, the stock is in a bearish trend below key moving averages, which further pressures the overall score, while valuation is inconclusive due to losses and no dividend yield data.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global next-generation immunotherapy company focused on developing novel treatments for cancer and other serious diseases. Its diversified oncology portfolio spans mRNA cancer immunotherapies, next‑generation immunomodulators, antibody-drug conjugates and CAR T cell therapies, with a growing emphasis on lung cancer across disease stages.
Average Trading Volume: 1,163,717
Technical Sentiment Signal: Sell
Current Market Cap: $22.22B
Learn more about BNTX stock on TipRanks’ Stock Analysis page.